Assessment of the Construct Validity of the Lupus Low Disease Activity State (LLDAS) - an Expert Opinion Case Study

被引：0
|
作者：
Golder, Vera [1 ]
Huq, Molla [2 ]
Franklyn, Kate [3 ]
Calderone, Alicia [4 ]
Lateef, Aisha [5 ]
Lau, Chak Sing [6 ]
Navarra, Sandra V. [7 ]
Godfrey, Timothy [4 ]
Oon, Shereen [4 ]
Hoi, Alberta Y. [3 ]
Morand, Eric F. [3 ]
Nikpour, Mandana [8 ]
机构：
[1] Monash Univ, Ctr Inflammatory Dis, Southern Clin Sch, Melbourne, Vic, Australia
[2] Univ Melbourne, Dept Med Rheumatol, Melbourne, Vic, Australia
[3] Monash Univ, Ctr Inflammatory Dis, Melbourne, Vic, Australia
[4] St Vincents Hosp, 63 Sutton St, Melbourne, Vic, Australia
[5] Natl Univ Hlth Syst, Med Rheumatol, Singapore, Singapore
[6] Queen Mary Hosp, Univ Dept Med, Hong Kong, Hong Kong, Peoples R China
[7] Univ Santo Tomas Hosp, Rheumatol, Manila, Philippines
[8] Univ Melbourne, Melbourne, Vic, Australia
来源：
ARTHRITIS & RHEUMATOLOGY | 2016年 / 68卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
790
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab
    Morand, Eric F.
    Trasieva, Teodora
    Berglind, Anna
    Illei, Gabor G.
    Tummala, Raj
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (05) : 706 - 713
  • [32] Lupus Low Disease Activity State (LLDAS) Achievement with Deucravacitinib, an Oral, Selective, Allosteric Tyrosine Kinase 2 Inhibitor, in a Phase 2 Trial in SLE
    Morand, Eric
    Hobar, Coburn
    Pomponi, Samantha
    Koti, Ravi
    Wegman, Thomas
    van Vollenhoven, Ronald
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 2961 - 2963
  • [33] Molecular Characterisation of Remission and Lupus Low Disease Activity State (LLDAS) by Whole-Blood Transcriptome-Based Pathways in a Pan-European Systemic Lupus Erythematosus Cohort
    Parodis, Ioannis
    Lindblom, Julius
    Barturen, Guillermo
    Ortega Castro, Rafaela
    Cervera, Ricard
    Pers, Jacques-Olivier
    Genre Romero, Fernanda
    Hiepe, Falk
    Gerosa, Maria
    Kovacs, Laszlo
    De langhe, Ellen
    Piantoni, Silvia
    Stummvoll, Georg
    Vasconcelos, Carlos
    Vigone, Barbara
    Witte, Torsten
    Alarcon-Riquelme, Marta
    Beretta, Lorenzo
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 3379 - 3382
  • [34] Predictors of Remission (on and off Treatment) and Lupus Low Disease Activity State (LLDAS) in Systemic Lupus Erythematosus (SLE): Data from a Multinational, Multicenter SLICC (Systemic Lupus International Collaborating Clinics) Cohort
    Ugarte-Gil, Manuel
    Ruiz-Irastorza, Guillermo
    Gladman, Dafna
    Urowitz, Murray
    Clarke, Ann
    Hanly, John
    Gordon, Caroline
    Bae, Sang-Cheol
    Romero-Diaz, Juanita
    Sanchez-Guerrero, Jorge
    Bernatsky, Sasha
    Wallace, Daniel
    Isenberg, David
    Rahman, Anisur
    Merrill, Joan
    Fortin, Paul R.
    Bruce, Ian N.
    Petri, Michelle
    Ginzler, Ellen
    Dooley, Mary Anne
    Ramsey-Goldman, Rosalind
    Manzi, Susan
    Jnsen, Andreas
    van Vollenhoven, Ronald F.
    Aranow, Cynthia
    Mackay, Meggan
    Lim, S. Sam
    Inanc, Murat
    Kalunian, Kenneth
    Jacobsen, Soren
    Peschken, Christine
    Kamen, Diane
    Askanase, Anca
    Pons-Estel, Bernardo A.
    Alarcn, Graciela
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 2639 - 2641
  • [35] Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation study
    Golder, Vera
    Kandane-Rathnayake, Rangi
    Huq, Moth
    Nim, Hieu T.
    Louthrenoo, Worawit
    Luo, Shue Fen
    Wu, Yeong-jian Jan
    Lateef, Aisha
    Sockalingam, Sargunan
    Navarra, Sandra, V
    Zamora, Leonid
    Hamijoyo, Laniyati
    Katsumata, Yasuhiro
    Harigai, Masayoshi
    Chan, Madelynn
    O'Neill, Sean
    Goldblatt, Fiona
    Lau, Chak Sing
    Li, Zhan Guo
    Hoi, Alberta
    Nikpour, Mandan
    Morand, Eric F.
    LANCET RHEUMATOLOGY, 2019, 1 (02): : E95 - E102
  • [36] Utility of the Lupus Low Disease Activity State (LLDAS) in Discriminating Responders in the BLISS-52 and BLISS-76 Phase 3 Trials of Intravenous Belimumab in Systemic Lupus Erythematosus
    Oon, Shereen
    Huq, Molla
    Golder, Vera
    Ong, Emily
    Morand, Eric
    Nikpour, Mandana
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [37] THE LUPUS LOW DISEASE ACTIVITY STATE (LLDAS) DEFINITION DISCRIMINATES RESPONDERS IN A SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) TRIAL: POST-HOC ANALYSIS OF THE PHASE IIB MUSE TRIAL OF ANIFROLUMAB
    Morand, E.
    Berglind, A.
    Sheytanova, T.
    Tummala, R.
    Illei, G.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 50 - 50
  • [38] Observer Agreement and Construct Validity in Central Endoscopic Assessment of Disease Activity in Ulcerative Colitis
    Pola, Suresh
    Feagan, Brian G.
    Fahmy, Marianne
    Vandervoort, Margaret K.
    D'Haens, Geert R.
    McDonald, John W.
    Panaccione, Remo
    Rutgeerts, Paul J.
    Travis, Simon
    Van Assche, Gert A.
    Vermeire, Severine
    Loftus, Edward V.
    Zou, Guangyong
    Nelson, Sigrid
    Sandborn, William
    Levesque, Barrett
    GASTROENTEROLOGY, 2013, 144 (05) : S763 - S763
  • [39] QUANTITATIVE ULTRASOUND FOR ASSESSMENT OF DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS: RELIABILITY AND CONSTRUCT VALIDITY
    Goswami, R. P.
    Ghosh, A.
    Lahiri, D.
    Ghosh, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1423 - 1424
  • [40] VALIDITY OF RETROSPECTIVE DISEASE-ACTIVITY ASSESSMENT IN SYSTEMIC LUPUS-ERYTHEMATOSUS
    ARCESALINAS, A
    CARDIEL, MH
    GUZMAN, J
    ALCOCERVARELA, J
    ARTHRITIS AND RHEUMATISM, 1995, 38 (09): : 417 - 417
12345